Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated

BACKGROUND: The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations. METHODS: RSV-seronegative children aged 6–24 months received a single intranasal dose of 10(5) plaque-forming units (PFU) of LIDcpΔM2-2 or placebo....

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, Coleen K, Karron, Ruth, Muresan, Petronella, McFarland, Elizabeth J, Perlowski, Charlotte, Libous, Jennifer, Thumar, Bhagvanji, Gnanashanmugam, Devasena, Moye, Jack, Schappell, Elizabeth, Barr, Emily, Rexroad, Vivian, Aziz, Mariam, Deville, Jaime, Rutstein, Richard, Yang, Lijuan, Luongo, Cindy, Collins, Peter, Buchholz, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559275/
https://www.ncbi.nlm.nih.gov/pubmed/31211158
http://dx.doi.org/10.1093/ofid/ofz212
Descripción
Sumario:BACKGROUND: The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations. METHODS: RSV-seronegative children aged 6–24 months received a single intranasal dose of 10(5) plaque-forming units (PFU) of LIDcpΔM2-2 or placebo. RSV serum antibodies, vaccine infectivity, and reactogenicity were assessed. RESULTS: Four of 11 (36%) vaccinees shed vaccine virus with median peak titers of 1.6 log(10) PFU/mL by quantitative culture and 4.5 log(10) copies/mL by polymerase chain reaction; 45% had ≥4-fold rise in serum-neutralizing antibodies. Respiratory symptoms or fever were common in vaccinees (64%) and placebo recipients (6/6, 100%). CONCLUSIONS: RSV LIDcpΔM2-2 is overattenuated. Clinical Trial Numbers. NCT02890381, NCT02948127.

Ejemplares similares